Sabrina Serani

This week’s edition of The Targeted Pulse spotlights 5 key developments shaping the landscape of targeted oncology.

In the MIDAS trial, ASCT showed no added MRD benefit over Isa-KRd in newly diagnosed myeloma, raising questions about transplant timing.

FDA's new draft guidance enhances drug development for myelodysplastic syndromes, focusing on trial design, patient selection, and safety reporting.

Adcentrx Therapeutics advances gastric cancer treatment with FDA orphan drug designation for ADRX-0405, a promising antibody-drug conjugate in clinical trials.

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant melanoma.

FDA designates MB-101 CAR T-cell therapy for glioblastoma, highlighting its potential in treating aggressive brain tumors with innovative combination strategies.

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive malignancy.

Ruxolitinib shows sustained efficacy and safety in treating steroid-refractory chronic graft-vs-host disease, outperforming standard therapies over three years.

From FDA approvals streamlining access to critical therapies to new breakthroughs in challenging malignancies, the field of cancer care continues to demonstrate remarkable progress.

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with extensive-stage small cell lung cancer.

Discover groundbreaking advancements in GI cancer treatments from ASCO 2025, highlighting innovative therapies and improved patient outcomes.

Preliminary data highlights gedatolisib's potential in treating mCRPC and HER2+ mBC, showcasing promising efficacy and a favorable safety profile.

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after chemotherapy.

A new trial optimizes rhenium Re 186 obisbemeda dosing for treating leptomeningeal metastases, aiming to enhance safety and efficacy in CNS cancer therapy.

The SonoClear System revolutionizes neurosurgery with FDA breakthrough designation, enhancing ultrasound imaging for safer tumor resections in glioma surgeries.

The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, AI-driven urine test.

A phase 2a trial shows tigilanol tiglate achieves an 80% response rate in soft tissue sarcoma, offering hope for effective treatment options.

Elraglusib shows promise in enhancing survival rates for metastatic pancreatic cancer, particularly in high-risk patients with liver metastases.

Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, and CRC through targeted therapies and combinations.

New combination therapy of relacorilant and nab-paclitaxel shows promise in extending survival for patients with platinum-resistant ovarian cancer.

New study reveals mosunetuzumab and polatuzumab vedotin significantly improve outcomes for patients with relapsed large B-cell lymphoma, offering a chemotherapy-free option.

FDA prioritizes review of revumenib for relapsed NPM1-mutant AML, highlighting a breakthrough in targeted cancer therapies.

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ovarian cancer, regardless of HRD status.

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options.

Pirtobrutinib shows significant benefits in progression-free survival and tolerability for relapsed CLL patients compared to standard treatments.

A groundbreaking trial shows promising survival rates and low GVHD in patients receiving mismatched stem cell transplants, expanding treatment options for diverse populations.